6023-70-7

Basic information

• Product Name: (2E)-3-(4-chlorophenyl)-N-[4-(morpholin-4-yl)phenyl]prop-2-enamide
• CAS NO: 6023-70-7
• Molecular Formula: C₁₁H₁₁N₃O₂
• Molecular Weight: 342.8194
• Mol File: 6023-70-7.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 588.9°C at 760 mmHg
• Flash Point: 310°C
• Density: 1.285g/cm³
• Vapor Pressure: 7.58E-14mmHg at 25°C
• Refractive Index: 1.656
• CAS DataBase Reference: (2E)-3-(4-chlorophenyl)-N-[4-(morpholin-4-yl)phenyl]prop-2-enamide(CAS DataBase Reference)
• NIST Chemistry Reference: (2E)-3-(4-chlorophenyl)-N-[4-(morpholin-4-yl)phenyl]prop-2-enamide(6023-70-7)
• EPA Substance Registry System: (2E)-3-(4-chlorophenyl)-N-[4-(morpholin-4-yl)phenyl]prop-2-enamide(6023-70-7)

Safety Data

• Hazardous Substances Data: 6023-70-7(Hazardous Substances Data)

Usage

General Description

"(2E)-3-(4-chlorophenyl)-N-[4-(morpholin-4-yl)phenyl]prop-2-enamide" is a complex chemical compound with potential uses in biochemistry and pharmacology. Its structure primarily comprises a central prop-2-enamide backbone, bound to chlorophenyl and morpholinylphenyl substrates. The (2E) denotes the configuration of the double bond in the prop-2-enamide moiety, while the 4-chlorophenyl and the 4-(morpholin-4-yl)phenyl refer to the chlorinated phenyl and phenyl substituted with a morpholine ring, respectively. The potent combination of the functional groups may lend the compound different chemical reactivity, characteristic of amides. The precise properties, uses, and potency of this chemical compound would vary upon further investigation.

Upstream product

• 674-82-8 4-methyleneoxetan-2-one 
• 19335-11-6 1H-indazol-5-ylamine 
• 5394-63-8 2,2,6-trimethyl-4H-1,3-dioxin-4-one 

Downstream Products

• 1813527-81-9 4-(4-fluoro-3-((piridin-2-ylmethyl)carbamoyl)phenyl)-N-(1H-imidazol-5-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide 

Relevant articles and documents

Orthogonal Regulation of Nucleophilic and Electrophilic Sites in Pd-Catalyzed Regiodivergent Couplings between Indazoles and Isoprene

Depending on the reactant property and reaction mechanism, one major regioisomer can be favored in a reaction that involves multiple active sites. Herein, an orthogonal regulation of nucleophilic and electrophilic sites in the regiodivergent hydroamination of isoprene with indazoles is demonstrated. Under Pd-hydride catalysis, the 1,2- or 4,3-insertion pathway with respect to the electrophilic sites on isoprene could be controlled by the choice of ligands. In terms of the nucleophilic sites on indazoles, the reaction occurs at either the N1- or N2-position of indazoles is governed by the acid co-catalysts. Preliminary experimental studies have been performed to rationalize the mechanism and regioselectivity. This study not only contributes a practical tool for selective functionalization of isoprene, but also provides a guide to manipulate the regioselectivity for the N-functionalization of indazoles.

Utilizing a structure-based docking approach to develop potent G protein-coupled receptor kinase (GRK) 2 and 5 inhibitors

G protein-coupled receptor (GPCR) kinases (GRKs) regulate the desensitization and internalization of GPCRs. Two of these, GRK2 and GRK5, are upregulated in heart failure and are promising targets for heart failure treatment. Although there have been several reports of potent and selective inhibitors of GRK2 there are few for GRK5. Herein, we describe a ligand docking approach utilizing the crystal structures of the GRK2–Gβγ·GSK180736A and GRK5·CCG215022 complexes to search for amide substituents predicted to confer GRK2 and/or GRK5 potency and selectivity. From this campaign, we successfully generated two new potent GRK5 inhibitors, although neither exhibited selectivity over GRK2.

Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases

Recent studies using known Rho-associated kinase isoform 1 (ROCK1) inhibitors along with cellular and molecular biology data have revealed a pivotal role of this enzyme in many aspects of cardiovascular function. Here we report a series of ROCK1 inhibitors which were originally derived from a dihydropyrimidinone core 1. Our efforts focused on the optimization of dihydropyrimidine 2, which resulted in the identification of a series of dihydropyrimidines with improved pharmacokinetics and P450 properties.